{
  "ticker": "RHY",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974955",
  "id": "02974955",
  "pages": 11,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0907",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mc2n242jwvnz.pdf",
  "summary": "### **Summary of ASX Announcement \u2013 Rhythm Biosciences Ltd (ASX: RHY)**  \n**Type:** **Appendix 4C (Quarterly Report)**  \n\n#### **Key Highlights:**  \n- **ColoSTAT\u00ae Progress:**  \n  - Final production validation phase achieved; meets clinical benchmarks (89% sensitivity, 99% NPV).  \n  - Algorithm validated using clinical samples; NATA accreditation in progress.  \n\n- **Genetype Commercialisation:**  \n  - First strategic partnership secured; NATA accreditation reinstated for risk assessment portfolio.  \n  - Commercial pipeline expanding; FY25 revenue aligned with acquisition model.  \n\n- **Financials (Q4 FY25):**  \n  - **Cash balance:** AUD $1.397M (plus $85K in term deposits).  \n  - **Net operating cash outflow:** AUD ($1.891M).  \n  - **Funding liquidity:** 0.81 quarters of runway (AUD $1.537M total available funding).  \n  - **RDTI funding:** AUD $1M secured (non-dilutive).  \n\n- **Corporate Updates:**  \n  - Chairman transition: Otto Buttula to step down at 2025 AGM; Gavin Fox-Smith appointed successor.  \n  - Shareholder discount programs announced for geneType\u2122 (15% off) and future ColoSTAT\u00ae kits.  \n\n#### **Material Risks:**  \n- Limited operating cash runway (<2 quarters) \u2013 reliant on near-term capital raising or commercial milestones (ColoSTAT\u00ae launch).  \n\n**Note:** No capital raising or material M&A disclosed; focus remains on commercial readiness.",
  "usage": {
    "prompt_tokens": 6513,
    "completion_tokens": 332,
    "total_tokens": 6845,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T23:14:49.705892"
}